New Analysis Identifies Patient Populations With Cancer-associated VTE Who Could Benefit From Treatment With Oral, Once-daily LIXIANA® (edoxaban)
Munich (ots/PRNewswire) - - Hokusai-VTE CANCER study showed that oral edoxaban is non-inferior to subcutaneous injectable dalteparin, for the composite outcome of recurrent venous thromboembolism (VTE) and major bleeding in cancer-associated VTE - This analysis provides benefit/risk assessment in different types of ...